The Indian Council of Medical Research (ICMR) has developed the country’s first indigenous malaria vaccine named AdFalciVax. This recombinant vaccine was created jointly by the Regional Medical Research Centre (RMRC) in Bhubaneswar, the National Institute of Malaria Research (NIMR), and the Department of Biotechnology’s National Institute of Immunology (DBT-NII).
AdFalciVax specifically targets Plasmodium falciparum, the deadliest malaria parasite. It not only protects individuals from infection but also prevents transmission through mosquitoes, breaking the disease cycle. Health experts believe this vaccine could be a turning point in India’s fight against malaria.
Pre-clinical studies revealed strong immune responses and long-lasting protection. Unlike traditional vaccines, AdFalciVax offers broader coverage and remains stable at room temperature for up to nine months. This feature makes it easier to transport and store in remote areas where refrigeration is often unavailable.
The vaccine is produced using the safe bacterium Lactococcus lactis. For nationwide production, ICMR has licensed five companies: Indian Immunologicals Limited, TexInvention Lifecare, Panacea Biotech, Biological E Limited, and Zydus Lifesciences. The first batch is expected to be available by the end of this year, raising hopes for large-scale malaria control.
